BR112021019959A2 - Anticorpo biespecífico, e, formulação farmacêutica - Google Patents

Anticorpo biespecífico, e, formulação farmacêutica

Info

Publication number
BR112021019959A2
BR112021019959A2 BR112021019959A BR112021019959A BR112021019959A2 BR 112021019959 A2 BR112021019959 A2 BR 112021019959A2 BR 112021019959 A BR112021019959 A BR 112021019959A BR 112021019959 A BR112021019959 A BR 112021019959A BR 112021019959 A2 BR112021019959 A2 BR 112021019959A2
Authority
BR
Brazil
Prior art keywords
bispecific antibody
pharmaceutical formulation
site capable
antigen binding
binding site
Prior art date
Application number
BR112021019959A
Other languages
English (en)
Inventor
Henrik Østergaard
Jens Breinholt
S Gandhi Prafull
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112021019959A2 publication Critical patent/BR112021019959A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

anticorpo biespecífico, e, formulação farmacêutica. a invenção se refere a um anticorpo biespecífico compreendendo um primeiro sítio de ligação ao antígeno capaz de se ligar ao fator vii(a) e um segundo sítio de ligação ao antígeno capaz de se ligar a tlt-1, formulações farmacêuticas compreendendo tais anticorpos biespecíficos e seus usos.
BR112021019959A 2019-04-17 2020-04-15 Anticorpo biespecífico, e, formulação farmacêutica BR112021019959A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19169704 2019-04-17
EP19213867 2019-12-05
PCT/EP2020/060579 WO2020212415A1 (en) 2019-04-17 2020-04-15 Bispecific antibodies

Publications (1)

Publication Number Publication Date
BR112021019959A2 true BR112021019959A2 (pt) 2022-02-08

Family

ID=70189980

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019959A BR112021019959A2 (pt) 2019-04-17 2020-04-15 Anticorpo biespecífico, e, formulação farmacêutica

Country Status (15)

Country Link
US (2) US11325983B2 (pt)
EP (1) EP3956359A1 (pt)
JP (2) JP7297928B2 (pt)
KR (2) KR20240046282A (pt)
CN (1) CN113692415A (pt)
AU (1) AU2020259982A1 (pt)
BR (1) BR112021019959A2 (pt)
CA (1) CA3135632A1 (pt)
CL (1) CL2021002710A1 (pt)
CO (1) CO2021014072A2 (pt)
IL (1) IL286757A (pt)
MA (1) MA55705A (pt)
MX (1) MX2021012365A (pt)
PE (1) PE20212262A1 (pt)
WO (1) WO2020212415A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012365A (es) * 2019-04-17 2021-11-17 Novo Nordisk As Anticuerpos biespecificos.
CN116137870A (zh) 2020-10-12 2023-05-19 日本制铁株式会社 热浸镀锌钢板
WO2023150677A2 (en) * 2022-02-03 2023-08-10 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541275B1 (en) 1988-02-03 2003-04-01 Dade Behring Inc. Immunoassay for F1.2 prothrombin fragment
TW212184B (pt) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH05168494A (ja) 1991-05-17 1993-07-02 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
BR9508402A (pt) 1994-07-11 1997-10-21 Univ Texas Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE19802139C1 (de) 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
US20040180409A1 (en) 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
DE10354403A1 (de) 2003-11-20 2005-06-23 Dade Behring Marburg Gmbh Gegen das Prothrombin-Fragment F 1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
WO2007115953A1 (en) 2006-04-07 2007-10-18 Novo Nordisk Health Care Ag Covalent factor vii-tissue factor complex
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
KR20110022604A (ko) 2008-05-16 2011-03-07 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
CN102574908B (zh) 2009-08-27 2018-08-03 诺沃—诺迪斯克有限公司 组织因子向活化的血小板的靶向
JP5918750B2 (ja) 2010-04-08 2016-05-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔｒｅｍ様転写物１（ｔｌｔ−１）から誘導された阻害性ペプチドおよびその使用
SI2591006T1 (sl) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
JP6042335B2 (ja) 2010-09-15 2016-12-14 ノヴォ ノルディスク アー／エス 細胞取込みが低下した第ｖｉｉｉ因子変異体
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
JP6309273B2 (ja) 2011-03-02 2018-04-11 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 活性化血小板上のｔｌｔ−１に対する凝固因子の標的化
CN110023339A (zh) * 2016-09-23 2019-07-16 Csl有限公司 凝血因子结合蛋白及其应用
MX2021012365A (es) * 2019-04-17 2021-11-17 Novo Nordisk As Anticuerpos biespecificos.

Also Published As

Publication number Publication date
JP2022529036A (ja) 2022-06-16
KR20210153639A (ko) 2021-12-17
CA3135632A1 (en) 2020-10-22
US11325983B2 (en) 2022-05-10
MX2021012365A (es) 2021-11-17
JP2023116676A (ja) 2023-08-22
MA55705A (fr) 2022-02-23
PE20212262A1 (es) 2021-11-29
IL286757A (en) 2021-10-31
US20220213218A1 (en) 2022-07-07
CL2021002710A1 (es) 2022-05-27
JP7297928B2 (ja) 2023-06-26
CO2021014072A2 (es) 2022-01-17
WO2020212415A1 (en) 2020-10-22
EP3956359A1 (en) 2022-02-23
CN113692415A (zh) 2021-11-23
KR102652906B1 (ko) 2024-04-01
AU2020259982A1 (en) 2021-10-28
US20220064329A1 (en) 2022-03-03
KR20240046282A (ko) 2024-04-08

Similar Documents

Publication Publication Date Title
BR112021019959A2 (pt) Anticorpo biespecífico, e, formulação farmacêutica
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
BR112016026811A2 (pt) formulação de anticorpo
EA202192405A1 (ru) Составы антител против il-36r
MX2019007347A (es) Anticuerpo anti-cd3 y moleculas que comprenden el anticuerpo.
ECSP10010056A (es) ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
EA202092202A1 (ru) Конструкции антител к ror
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
CL2021001037A1 (es) Formulación de anticuerpos
EA201992027A1 (ru) Водный состав антитела против pd-l1
MX2021005085A (es) Formulacion de anticuerpo.
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
WO2018119351A8 (en) Anti-sez6l2 antibodies and antibody drug conjugates
CL2021001441A1 (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932)
WO2021118930A3 (en) Anti-pd-l1 antibody formulations
BR112023002984A2 (pt) Formulações de anticorpo terapêutico
MX2022005836A (es) Formulacion estable de anticuerpos acuosos.